Pitavastatin demonstrates sustained efficacy, tolerability and LDL-C target attainment over 52 weeks

Pitavastatin represents effective long-term treatment option

20.04.2011

Pitavastatin demonstrates sustained efficacy, tolerability and LDL-C target attainment over 52 weeks. Pitavastatin represents effective long-term treatment option for patients with primary hypercholesterolaemia or combined dyslipidaemia.

Wokingham, UK, 28th April 2010. New long-term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who received 4mg of pitavastatin, 74% and 73.5% achieved NCEP* and EAS* low-density lipoprotein cholesterol (LDL-C) targets at 52 weeks, respectively. At the end of this open-label one-year extension study, reductions in LDL-C observed during previous 12-week double-blind phase III studies were maintained (104.3 mg/dL at week 52 compared with 105.6 mg/dL at the end of the double-blind phase). Furthermore, high-density lipoprotein cholesterol (HDL-C) levels rose continually over 52 weeks, with an overall increase of 14.3% from initial baseline, while changes in other.

Download Material

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X